Peritoneal carcinomatosis is a common metastatic pattern in ovarian, gastric, colorectal, and appendiceal cancer; systemic chemotherapy is the current standard of care for peritoneal metastatic disease; however, in a subset of patients its beneficial effect remains questionable. More effective perioperative chemotherapy is needed. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new treatment that applies chemotherapeutic drugs into the peritoneal cavity as an aerosol under pressure. It's a safe and feasible approach that improves local bioavailability of chemotherapeutic drugs as compared with conventional intraperitoneal chemotherapy. Till now the drugs used in PIPAC for the treatment of the peritoneal carcinomatosis (PC) are cisplatin, doxorubicin, and oxaliplatin; as of yet, there are no data comparing different drug formulations and dosage schedules of PIPAC. Pegylated liposomal doxorubicin 1.5 mg/sm was aerosolized in PIPAC procedures. Pharmacokinetics analysis of 10 procedures performed with conventional doxorubicin solution at the dose of 1.5 mg/m were compared to 15 procedures with the same dose of pegylated liposomal doxorubicin (PLD). Significant differences between experimental groups were detected by one-way ANOVA followed by Bonferroni correction; a p value < 0.05 was considered statistically significant. A statistically different doxorubicin tissue concentration was observed for the doxorubicin solution compared to pegylated liposomal doxorubicin in the right parietal peritoneum and right diaphragm. In the Caelyx series a mean tissue concentration of 1.27 ± 1.33 mg/g was reported, while in the second one we registered a mean concentration of 3.1 ± 3.7 mg/g. The delivery of nano-particles in PIPAC was feasible, but pegylated liposomal concentrations are lower than standard doxorubicin formulation. Probably mechanical and physical properties of pressurized aerosol chemotherapy might alter their stability and cause structural disintegration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603215PMC
http://dx.doi.org/10.3389/fphar.2019.00669DOI Listing

Publication Analysis

Top Keywords

pegylated liposomal
20
liposomal doxorubicin
16
aerosol chemotherapy
12
doxorubicin
9
pressurized intraperitoneal
8
intraperitoneal aerosol
8
peritoneal carcinomatosis
8
pipac treatment
8
chemotherapeutic drugs
8
doxorubicin solution
8

Similar Publications

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most prevalent form of late-life dementia. The ε2 allele of the APOE gene encoding apolipoprotein E (APOE2) is associated with lower susceptibility to AD among the three genotypes (ε2, ε3, ε4), while APOE4 is the strongest genetic risk factor for late-onset AD. APOE plays a critical role in maintaining synaptic plasticity and neuronal function by controlling lipid homeostasis, with APOE2 having a superior function.

View Article and Find Full Text PDF

pH-Responsive Polyethylene Glycol Engagers for Enhanced Brain Delivery of PEGylated Nanomedicine to Treat Glioblastoma.

ACS Nano

January 2025

Department of Biological Science and Technology, Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan.

The blood-brain barrier (BBB) remains a major obstacle for effective delivery of therapeutics to treat central nervous system (CNS) disorders. Although transferrin receptor (TfR)-mediated transcytosis is widely employed for brain drug delivery, the inefficient release of therapeutic payload hinders their efficacy from crossing the BBB. Here, we developed a pH-responsive anti-polyethylene glycol (PEG) × anti-TfR bispecific antibody (pH-PEG engager) that can complex with PEGylated nanomedicine at physiological pH to trigger TfR-mediated transcytosis in the brain microvascular endothelial cells, while rapidly dissociating from PEGylated nanomedicine at acidic endosomes for efficient release of PEGylated nanomedicine to cross the BBB.

View Article and Find Full Text PDF

Bacterial removal using liposomes and an anionic adsorber.

J Biosci Bioeng

December 2024

Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Sakyo-ku, Kyoto 606-8502, Japan.

Extracorporeal blood purification techniques using magnetic beads, which physically remove bacteria, fungi, viruses, and cytokines (disease agents) from the blood causing sepsis, have been studied. However, magnetic bead influx, which causes hemolysis and cytotoxicity, is an important issue. This study proposed a novel method for removing Escherichia coli from the blood using liposomes with high biocompatibility.

View Article and Find Full Text PDF

Red grapes contain resveratrol (Resv), a polyphenol with anti-inflammatory, anti-diabetic, and anticancer properties. In this study, in silico molecular docking was used to assess the binding affinity of Resv to target proteins. Resv was encapsulated in PEGylated liposomes (LNPs) using Phospholipon 90G, cholesterol, and DSPE-mPEG.

View Article and Find Full Text PDF

Detachable Cyclic Poly(ethylene glycol)-Embedded Choline Phosphate Liposome Used for Long-Acting and Accurate Cancer Chemo-Immunotherapy with High Security.

ACS Appl Mater Interfaces

December 2024

Key Laboratory of Polyoxometalate and Reticular Material Chemistry of Ministry of Education, School of Chemistry, Northeast Normal University, Changchun 130024, China.

Liposomes have attracted attention in biomedicine and pharmacy for their benefits including reduced toxicity, extended pharmacokinetics, and biocompatibility. However, their limitations include susceptibility to blood clearance, rapid disintegration, and lack of functionality, restricting their further applications. To address these challenges, inspired by the unique topological features of cyclic polymers and the specific binding property of the choline phosphate (CP) lipid, dipole-dipole interactions between CP molecules are utilized to create a detachable cyclic PEG-embedded CP liposome (d-cycPEG-lipo).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!